Genitourinary tract patent update

被引：17
作者：
Smith, CP [1 ]
Chancellor, MB [1 ]
机构：
[1] Univ Pittsburgh, Sch Med, Dept Urol, Pittsburgh, PA USA
来源：
EXPERT OPINION ON THERAPEUTIC PATENTS | 2001年 / 11卷 / 01期
基金：
美国国家卫生研究院;
关键词：
gene therapy; stem cells; stress urinary incontinence; tissue engineering; urge urinary incontinence; urinary incontinence;
D O I：
10.1517/13543776.11.1.17
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
The treatment of urinary incontinence is a. booming business with over $26 billion being spent annually. Pharmacological research is rapidly increasing as scientists attempt to modulate complex micturition pathways to result in meaningful clinical improvement of conditions such as urge and stress incontinence. Antimuscarinic agents remain the mainstay in the treatment of urge incontinence with newer agents having, functional selectivity for the bladder to prevent unwanted anticholinergic side effects. Other exciting pharmacological targets to treat urinary incontinence include beta3 adrenoceptor agonists and agents that affect afferent pathways (i,e. neurokinin antagonists). Non-pharmacologic treatment of urinary incontinence includes various injectable agents, and electrical or magnetic stimulation. Finally, recent patents have addressed tissue engineering techniques to treat urinary incontinence via cultured chondrocytes, bladder smooth muscle, or muscle derived stem cells.
引用
收藏
页码：17 / 31
页数：15
相关论文
共 136 条
  • [1] ABBOTT LABS, 2000, Patent No. 0004027
  • [2] Abrams P, 1998, BRIT J UROL, V81, P801
  • [3] ABRAMS P, 1988, SCAND J UROL NEPHROL, P5
  • [4] ABRAMS P, 1999, WHO 1 INT CONS INC
  • [5] ADV BIONICS CORP, 2000, Patent No. 6061596
  • [6] AKZO NOBEL NV, 1998, Patent No. 863136
  • [7] Alisi A., 1998, PCT Int. Appl., Patent No. [WO 9846589, 9846589]
  • [8] ALTENBACH RJ, 2000, Patent No. 0007997
  • [9] AM HOME PRODUCTS COR, 1998, Patent No. 9802413
  • [10] AM HOME PRODUCTS COR, 1998, Patent No. 5750574
12345678910